Organization
IGM Biosciences
9 clinical trials
Clinical trial
An Open-Label, Multicenter, Phase 1 Study of IGM-7354 in Adult Participants With Relapsed and/or Refractory CancerStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
Treatment Guidelines for Expanded Access of Imvotamab (IGM-2323) in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas From IGM-2323-001Status:
Clinical trial
A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior TherapiesStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Severe Systemic Lupus Erythematosus Who Have Failed Standard TherapiesStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed CancersStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy VolunteersStatus: Terminated, Estimated PCD: 2022-06-15
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19Status: Terminated, Estimated PCD: 2022-05-06
Clinical trial
An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01